Eur J Cancer: Trastuzumab-lapatinib neoadjuvant treatment of HER2+ early breast cancer patients: from the CHER-Lob study

The phase II randomized clinical study of Cher-LOB is mainly to evaluate the efficacy of trastuzumab-lapatinib in neoadjuvant therapy for HER2+ early breast cancer
.

Patients with HER2-positive breast cancer at stage II-IIIA were randomly assigned (1:1:1) to receive paclitaxel-anthracycline chemotherapy combined with trastuzumab (group A) or lapatinib (group B) or trastuzumab Tocilizumab + lapatinib (group C) was used as a neoadjuvant therapy

The phase II randomized clinical study of Cher-LOB is mainly to evaluate the efficacy of trastuzumab-lapatinib in neoadjuvant therapy for HER2+ early breast cancer

There were 36, 39 and 46 patients in groups A, B and C, respectively
.

The median follow-up was 9 years (95% CI 8.

There were 36, 39 and 46 patients in groups A, B and C, respectively

RFS comparison

 RFS comparison

The 5-year RFS rate of patients with pCR was higher than that of patients without pCR (97.
3% vs 72.
7%, HR=0.
12, 95% CI 0.
03-0.
49; log-rank P <0.
001)
.

ER-negative patients (pCR vs no-pCR: 94.

The 5-year RFS rate of patients with pCR was higher than that of patients without pCR (97.

pCR layered RFS and OS

pCR layered RFS and OS

Similarly, the 5-year OS of patients with pCR was higher than that of patients without pCR (97.
2% vs 89.
5%, HR=0.
12, 95% CI 0.
03-0.
49; log-rank P= 0.
028)
.

Similarly, the 5-year OS of patients with pCR was higher than that of patients without pCR (97.
2% vs 89.
5%, HR=0.
12, 95% CI 0.
03-0.
49; log-rank P= 0.
028)
.

The 5-year OS of patients with pCR was higher than that of patients without pCR (97.

Tumor infiltrating lymphocytes (TILs) are significantly related to RFS (HR=0.

          Prognostic factors of RFS

Prognostic factors of RFS

84 patients can be assessed for the relationship between PAM50 subtype and prognosis
.

Among them, HER2 positive is 26.

84 patients can be assessed for the relationship between PAM50 subtype and prognosis

In summary, the Cher-LOB study survival analysis confirmed the prognostic effects of pCR and TILs, and suggested that trastuzumab combined with lapatinib can improve the prognosis of patients compared with trastuzumab

Original source:

Guarneri V, Dieci MV, Griguolo G, et al.
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial.
Eur J Cancer.
2021 Jun 18;153:133-141.
doi : 10.
1016/j.
ejca.
2021.
05.
018.
Epub ahead of print.
PMID: 34153715.

Guarneri V, Dieci MV, Griguolo G, et al.
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial.
Eur J Cancer.
2021 Jun 18;153:133-141.
doi : 10.
1016/j.
ejca.
2021.
05.
018.
Epub ahead of print.
PMID: 34153715.
Leave a message here